Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ribavirin mitigates Alzheimer's disease model phenotypes by enhancing lysosomal function and suppressing ISR.

Bioorganic chemistry - 15 Sept 2026

Yi Zhicheng, Yao Zihao, Wang Fuhao, Xu Meng, Deng Cui, Yao Wei, Chen Xinyi, Shi Jiaxin, Liu Fufeng, Dong Wei, Wang Xiangming

Abstract excerpt

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder for which effective therapies remain an urgent unmet need. This study investigated the therapeutic potential of the synthetic nucleoside analogue ribavirin in transgenic Caenorhabditis elegans (C. elegans) models of AD. We demonstrate that ribavirin specifically reduced the paralysis rate and improved short-term non-associative learning...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Animals, Genetically Modified

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caenorhabditis elegans

Share to Lysosomes

Share to Molecular Structure

Share to Neuroprotective Agents

Share to Peptide Fragments

Share to Ribavirin

Source

Identifiers

PMID: 42379016
DOI: 10.1016/j.bioorg.2026.110142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ribavirin mitigates Alzheimer's disease model phenotypes by enhancing lysosomal function and suppressing ISR.PMID 42379016Read ↗

Natural Bioactive Products and Alzheimer’s Disease Pathology: Lessons from Caenorhabditis elegans Transgenic ModelsSemantic proximity Read ↗

Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeuticsSemantic proximity Read ↗

Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s diseaseSemantic proximity Read ↗

Modeling Alzheimer’s Disease in Caenorhabditis elegansSemantic proximity Read ↗

Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicitySemantic proximity Read ↗

Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and HealthspanSemantic proximity Read ↗

Levels of Amyloid Beta (Aβ) Expression in the Caenorhabditis elegans Neurons Influence the Onset and Severity of Neuronally Mediated Phenotypes.Semantic proximity Read ↗

Use of Caenorhabditis elegans as a model to study Alzheimer’s disease and other neurodegenerative diseasesSemantic proximity Read ↗

A drug cocktail of rapamycin, acarbose, and phenylbutyrate enhances resilience to features of early-stage Alzheimer’s disease in aging miceSemantic proximity Read ↗

Studying the mechanisms of neurodegeneration: C. elegans advantages and opportunitiesSemantic proximity Read ↗

Resveratrol Enhances Associative Learning and Memory Function in C. elegans Models of Alzheimer’s Disease: A Chemotaxis-Based Behavioral AnalysisSemantic proximity Read ↗

Oolonghomobisflavans from <i>Camellia sinensis</i> disaggregate tau fibrils across Alzheimer’s disease modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.